Notice of Allowability	Application No.	Applicant(s)
	09/473,551	MILBRANDT ET AL.
	Examiner	Art Unit
	Olga N. Chernyshev	1646
The MAILING DATE of this communication appears All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT R of the Office or upon petition by the applicant. See 37 CFR 1.313	ears on the cover sheet with (OR REMAINS) CLOSED in the or other appropriate communication is sub	the correspondence address nis application. If not included cation will be mailed in due course. THIS
1. This communication is responsive to <u>12/1/3</u> .		
 The allowed claim(s) is/are <u>1 and 6-9</u>. The drawings filed on are accepted by the Examine 		
4. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some* c) None of the:		
 ☐ Certified copies of the priority documents have been received. 		
2. Certified copies of the priority documents have been received in Application No		
3. Copies of the certified copies of the priority documents have been received in this national stage application from the		
International Bureau (PCT Rule 17.2(a)). * Certified copies not received:		
 5. Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application) since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78. (a) The translation of the foreign language provisional application has been received. 6. Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121 since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78. 		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
7. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
 8. CORRECTED DRAWINGS (as "replacement sheets") must be submitted. (a) including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached 1) hereto or 2) to Paper No. 		
 (b) ☐ including changes required by the proposed drawing correction filed, which has been approved by the Examiner. (c) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No 		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the margin according to 37 CFR 1.121(d). 9. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the		
attached Examiner's comment regarding REQUIREMENT FOR THE	HE DEPOSIT OF BIOLOGICAL	_ MATERIAL.
Attachment(s)		
1☐ Notice of References Cited (PTO-892)	5 ☐ Notice of Information	al Patent Application (PTO-152)
 Notice of Draftperson's Patent Drawing Review (PTO-948) Information Disclosure Statements (PTO-1449 or PTO/SB/08) Paper No. 	6☐ Interview Summ	ary (PTO-413), Paper No
Examiner's Comment Regarding Requirement for Deposit of Biological Material		ement of Reasons for Allowance

EXAMINER'S AMENDMENT

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Daniel S. Kasten on January 13, 2004.

The application has been amended as follows:

Please amend claim 1 as follows:

Claim 1 (currently amended): A polypeptide which activates GFR α 1-RET but does not substantially activate GFR α 2-RET or GFR α 3-RET, wherein

- (a) said polypeptide comprises a persephin sequence <u>essentially as set forth in SEQ ID</u>

 NO: 1, and differing there from only by the presence of with substitutions in region F2a (amino acids 60-67 of SEQ ID NO: 1) and substitutions in region F2c (amino acids 77-83 of SEQ ID NO: 1),
- (b) the substitutions in region F2a comprise from four to eight amino acids that are identical to region F2a of a GDNF family ligand,
- (c) the substitutions in region F2c comprise from seven to eight amino acids that are identical to region F2c of a GDNF family ligand,
 - (d) the GDNF family ligand is a peptide of SEQ ID NO: 4.
- 2. Claims 1, 6-9 are allowed. Claims have been renumbered as 1-5, respectively.

Drawings

3. Figures 2-8 of the instant application are presented on separate pages or in separate panels. 37 C.F.R. § 1.84(u) (1) states that when partial views of a drawing which are intended to form one complete view, whether contained on one or several sheets, must be identified by the same number followed by a capital letter. For example, the three panels of Figure 2 in the instant specification should be renumbered "Figure 2A" – "Figure 2C" rather than "Figure 2, A, B, C". Applicant is reminded that once the drawings are changed to meet the separate numbering requirement of 37 C.F.R. § 1.84(u) (1), the specification should be amended to change the Brief Description of the Drawings and the rest of the specification to refer to each Figure accordingly. If, for example, Figure 2 is divided into Figures 2A-2C, then the Brief Description and all the references to this figure in the specification must refer to this Figure in the same manner.

In order to avoid abandonment of this application, correction is required in reply to the Office action. The correction will not be held in abeyance.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Olga N. Chernyshev whose telephone number is (703) 305-1003. The examiner can normally be reached on Monday to Friday 9 AM to 5 PM ET.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Yvonne Eyler can be reached on (703) 308-6564. The fax phone number for the organization where this application or proceeding is assigned is (703) 872-9306.

Certain papers related to this application may be submitted to Technology Center 1600 by facsimile transmission. Papers should be faxed to Technology Center 1600 via the PTO Fax

Application/Control Number: 09/473,551

Art Unit: 1646

Page 4

center located in Crystal Mall 1 (CM1). The faxing of such papers must conform with the notices published in the Official Gazette, 1156 OG 61 (November 16, 1993) and 1157 OG 94 (December 28, 1993) (see 37 C.F.R. § 1.6(d)0. NOTE: If Applicant *does* submit a paper by fax, the original signed copy should be retained by Applicant or Applicant's representative. NO DUPLICATE COPIES SHOULD BE SUBMITTED so as to avoid the processing of duplicate papers.

Official papers filed by fax should be directed to (703) 872-9306. If this number is out of service, please call the Group receptionist for an alternative number. Faxed draft or informal communications with the examiner should be directed to (703) 308-7939. Official papers should NOT be faxed to (703) 308-7939.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

Olga N. Chernyshev, Ph.D.

JOHN ULM PRIMARY EXAMINER GROUP 1800